EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the ubiquitin pathway in lymphoid malignancies

Boheng Li, Pieter Johan Adam Eichhorn, Wee-Joo Chng

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.216978 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024. Verfasst von Boheng Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Southwest University, Chongqing, China. Hauptthemen laut MEDLINE: Ubiquitination, Signal Transduction, Ubiquitin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ubiquitination and related cellular processes control a variety of aspects in human cell biology, and defects in these processes contribute to multiple illnesses. In recent decades, our knowledge about the pathological role of ubiquitination in lymphoid cancers and therapeutic strategies to target the modified ubiquitination system has evolved tremendously. Here we review the altered signalling mechanisms mediated by the aberrant expression of cancer-associated E2s/E3s and deubiquitinating enzymes (DUBs), which result in the hyperactivation of oncoproteins or the frequently allied downregulation of tumour suppressors. We discuss recent highlights pertaining to the several different therapeutic interventions which are currently being evaluated to effectively block abnormal ubiquitin-proteasome pathway and the use of heterobifunctional molecules which recruit the ubiquitination system to degrade or stabilize non-cognate substrates. This review aids in comprehension of ubiquitination aberrance in lymphoid cancers and current targeting strategies and elicits further investigations to deeply understand the link between cellular ubiquitination and lymphoid pathogenesis as well as to ameliorate corresponding treatment interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UbiquitinationSignal TransductionUbiquitinHumansAnimalsLymphomaMolecular Targeted TherapyAntineoplastic AgentsProteasome Endopeptidase ComplexDeubiquitinating Enzymes

Stichwörter der Autor:innen

Deubiquitinating enzyme (DUB)Immunomodulatory agent (IMiD)LymphomaMultiple myeloma (MM)Proteasome inhibitor (PI)Ubiquitination

Substanzen

UbiquitinAntineoplastic AgentsProteasome Endopeptidase ComplexDeubiquitinating Enzymes

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Southwest University, Chongqing, China.
  • Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Bentley, Western Australia, Australia; Curtin Medical School, Faculty of Health Sciences, Curtin University, Bentley, Western A…
  • Cancer Science Institute of Singapore, Singapore, Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, Singapore, Singapore; Department of Medicine, School of Medicine, Natio…

Zitieren

APA

Li, B., Adam Eichhorn, P. J., & Chng, W. J. (2024). Targeting the ubiquitin pathway in lymphoid malignancies. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216978

Vancouver

Li B, Adam Eichhorn PJ, Chng WJ. Targeting the ubiquitin pathway in lymphoid malignancies. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216978

BibTeX
@article{Li2024,
  author = {Li, Boheng and Adam Eichhorn, Pieter Johan and Chng, Wee-Joo},
  title = {Targeting the ubiquitin pathway in lymphoid malignancies},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.216978}
}
Kostenlos starten →